Back to Search
Start Over
The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study
- Source :
- United European Gastroenterol J, Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S, Belousova, E, D'Incà, R, Sartini, A, Valpiani, D, Giannotta, M, Misra, R, Arebi, N, Duricova, D, Bortlik, M, Gatt, K, Ellul, P, Pedersen, N, Kjeldsen, J, Andersen, K W, Andersen, V, Katsanos, K H, Christodoulou, D K, Sebastian, S, Barros, L, Magro, F, Midjord, J M, Nielsen, K R, Salupere, R, Kievit, H A, Kiudelis, G, Kupčinskas, J, Fumery, M, Gower-Rousseau, C, Kaimakliotis, I P, Schwartz, D, Odes, S, Lakatos, L, Lakatos, P L, Langholz, E, Munkholm, P & Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up-an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949, Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S, Belousova, E, D'Incà, R, Sartini, A, Valpiani, D, Giannotta, M, Misra, R, Arebi, N, Duricova, D, Bortlik, M, Gatt, K, Ellul, P, Pedersen, N, Kjeldsen, J, Andersen, K W, Andersen, V, Katsanos, K H, Christodoulou, D K, Sebastian, S, Barros, L, Magro, F, Midjord, J M M, Nielsen, K R, Salupere, R, Kievit, H A L, Kiudelis, G, Kupčinskas, J, Fumery, M, Gower-Rousseau, C, Kaimakliotis, I P, Schwartz, D, Odes, S, Lakatos, L, Lakatos, P L, Langholz, E, Munkholm, P & for the Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up : an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949, Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S & for the Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949, United European Gastroenterology Journal, United European Gastroenterology Journal, 2020, 8 (8), pp.949-960. ⟨10.1177/2050640620945949⟩
- Publication Year :
- 2020
-
Abstract
- BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.
- Subjects :
- Adult
Male
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
5-aminosalicylates
Population-based cohort
disease course
Disease
Severity of Illness Index
Disease course
Maintenance Chemotherapy
Population based cohort
Biological Factors
Young Adult
Crohn Disease
Internal medicine
Medicine
Humans
Immunologic Factors
In patient
Prospective Studies
Mesalamine
5-aminosalicylate
Colectomy
Crohn's disease
business.industry
Anti-Inflammatory Agents, Non-Steroidal
Inflammatory Bowel Disease
Gastroenterology
Middle Aged
medicine.disease
INCEPTION COHORT
Europe
Hospitalization
Treatment Outcome
Oncology
Disease Progression
Drug Therapy, Combination
Female
business
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 20506406 and 20506414
- Database :
- OpenAIRE
- Journal :
- United European Gastroenterol J, Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S, Belousova, E, D'Incà, R, Sartini, A, Valpiani, D, Giannotta, M, Misra, R, Arebi, N, Duricova, D, Bortlik, M, Gatt, K, Ellul, P, Pedersen, N, Kjeldsen, J, Andersen, K W, Andersen, V, Katsanos, K H, Christodoulou, D K, Sebastian, S, Barros, L, Magro, F, Midjord, J M, Nielsen, K R, Salupere, R, Kievit, H A, Kiudelis, G, Kupčinskas, J, Fumery, M, Gower-Rousseau, C, Kaimakliotis, I P, Schwartz, D, Odes, S, Lakatos, L, Lakatos, P L, Langholz, E, Munkholm, P & Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up-an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949, Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S, Belousova, E, D'Incà, R, Sartini, A, Valpiani, D, Giannotta, M, Misra, R, Arebi, N, Duricova, D, Bortlik, M, Gatt, K, Ellul, P, Pedersen, N, Kjeldsen, J, Andersen, K W, Andersen, V, Katsanos, K H, Christodoulou, D K, Sebastian, S, Barros, L, Magro, F, Midjord, J M M, Nielsen, K R, Salupere, R, Kievit, H A L, Kiudelis, G, Kupčinskas, J, Fumery, M, Gower-Rousseau, C, Kaimakliotis, I P, Schwartz, D, Odes, S, Lakatos, L, Lakatos, P L, Langholz, E, Munkholm, P & for the Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up : an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949, Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S & for the Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949, United European Gastroenterology Journal, United European Gastroenterology Journal, 2020, 8 (8), pp.949-960. ⟨10.1177/2050640620945949⟩
- Accession number :
- edsair.doi.dedup.....1b976eb381a6de1e92b92bbf2b2b2f7f
- Full Text :
- https://doi.org/10.1177/2050640620945949